Protagonist Therapeutics, Inc. Common Stock (NASDAQ: PTGX) last traded at $154.32, up 2.41% on the session. The quote above updates while this page is open; the figures below are drawn from Protagonist Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Protagonist Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker PTGX. Its market capitalisation is $9.99 billion.
Valuation measures for Protagonist Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $9.99B |
|---|---|
| Enterprise value | $9.61B |
| P/E ratio | 149.83 |
| Price / sales | 35.41 |
| Price / book | 11.87 |
| Beta | 0.15 |
Trailing-twelve-month figures tagged in Protagonist Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $281.99M |
|---|---|
| Net income (TTM) | $82.91M |
| EPS (TTM) | $1.03 |
| Operating margin | 20.69% |
| Return on equity | 9.85% |
| Cash | $420.08M |
Range and volume for PTGX over the past 52 weeks.
| 52-week high | $160.81 |
|---|---|
| 52-week low | $54.50 |
| Volume | 395.7K |
| Average volume | 686.2K |
| Previous close | $150.69 |
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.